AKT Inhibitor Compounds Selective Isoform Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies targeting AKT pathways face challenges due to rapid resistance development and the need for effective inhibitors that can selectively target AKT isoforms without affecting other proteins, particularly in cancers with hyperactivated AKT and PI3K pathway mutations.
Innovation Solution
Development of specific compounds, such as those represented by Formula (I), which are designed to inhibit AKT activity by targeting key residues and structures, potentially offering selective inhibition of AKT1 and AKT2 over AKT3, and are formulated for pharmaceutical use to treat various cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer therapies targeting AKT pathways are used, then some anti-cancer effect is achieved, but rapid resistance development occurs
Solution Approach 1:
The patent employs parameter changes by developing compounds with optimized chemical structures (Formula I with specific R1-R9 substituents) that alter the binding affinity and selectivity parameters toward AKT isoforms. This structural parameter optimization enables sustained inhibition efficacy and delays resistance development by targeting specific isoform variations that differ in cancer contexts.
Solution Approach 2:
The patent applies segmentation by designing compounds that selectively target specific AKT isoforms (AKT1, AKT2, AKT3) rather than all serine/threonine kinases. The selective inhibition of particular isoforms involved in cancer pathogenesis while sparing others reduces off-target effects and mitigates resistance development through isoform-specific therapeutic action.
2Adaptability or versatility
If broad-spectrum kinase inhibitors are used, then multiple kinase activities are inhibited, but selectivity for AKT isoforms is reduced
Solution Approach 1:
The patent applies local quality by designing compounds with specific substituent patterns (R1-R9 groups in Formula I) that create localized interaction features matching the unique binding pocket characteristics of AKT isoforms. This local structural optimization enables selective recognition of AKT isoform-specific residues while maintaining inhibitory activity, achieving both versatility and precision.
Solution Approach 2:
The patent uses the compound structure of Formula I as an intermediary that bridges the gap between broad kinase inhibition and selective AKT targeting. The molecular scaffold acts as a mediator that translates general kinase inhibitor pharmacophores into AKT-specific inhibitors through strategic substituent placement, enabling selective isoform inhibition with controlled versatility.
3Productivity
If AKT inhibition is achieved, then cell proliferation is reduced, but phosphorylation pathways may be dysregulated
Solution Approach 1:
The patent applies taking out by selectively removing (inhibiting) only the specific AKT isoforms that are hyperactivated in cancer contexts, rather than broadly inhibiting all phosphorylation pathways. This selective extraction of pathological AKT activity preserves normal phosphorylation signaling while reducing aberrant cell proliferation, maintaining pathway regulation reliability.
Data Source
AI summary
The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.